03-Nov-2020 - PerkinElmer, Inc.

PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million

Acquisition will enable PerkinElmer to better partner with academic and pharma/biopharma scientists to help meet today’s research challenges

PerkinElmer, Inc. and Horizon Discovery Group plc to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million). The transaction has a total enterprise value of approximately $368 million (£284 million), is expected to close in the first quarter of 2021 subject to customary closing conditions.

With this investment, PerkinElmer will expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. The acquisition will enable PerkinElmer to better partner with academic and pharma/biopharma scientists to help meet today’s research challenges. It will also provide an opportunity to provide important tools for exploring next generation cell engineering and customized cell lines for relevant biological models – important for the future of precision medicine.

Headquartered in Cambridge, UK, Horizon is a leading provider of CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings which help scientists better understand gene function, genetic disease drivers and biotherapeutics delivery. Horizon has approximately 400 employees across multiple countries, including the UK, the US and Japan and reported revenue from continuing operations of $75.5 million (£58.3 million) in 2019.

PerkinElmer’s discovery and applied genomics solutions feature a range of immunoassay platforms, high content screening (HCS) and in vivo imaging, along with microfluidics, robotic liquid handling technologies and next-generation sequencing library preparation kits.

Unifying PerkinElmer’s and Horizon’s complementary offerings across the genotypic and phenotypic approaches for drug discovery and development will help researchers accelerate decision making with better information, automated workflows and greater quality and control over data.

Commenting on the agreement, Prahlad Singh, President and Chief Executive Officer, PerkinElmer said, “One of the key fundamentals for molecular research and drug discovery is being able to knock down a gene or function and explore the results to discover actionable insights and new clinical trial candidates faster. We’re excited to team up with Horizon to not only add CRISPR and RNAi capabilities into our existing portfolio, but also to leverage our combined life sciences screening and applied genomics solutions to help propel the next phase of cell and gene research for precision medicine. PerkinElmer leads with science and creates total solutions to bring today’s leading innovations together for our customers, while also working at the cutting edge of what’s next. Today’s announcement delivers on both of these fronts.”

Facts, background information, dossiers
  • PerkinElmer
  • Horizon Discovery
  • acquisitions
More about PerkinElmer
More about Horizon Discovery
  • News

    Horizon Discovery appoints new CEO

    Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect. Terry joined Horizo ... more

    Horizon extends industry-leading gene editing IP portfolio

    Horizon Discovery Group announced the extension of their pre-existing non-exclusive, worldwide license agreement to significantly expand Horizon’s license coverage for the use of the CRISPR gene editing technology. This will enable Horizon to use CRISPR in multiple new areas across its prod ... more

    Horizon Discovery Group and Ventana Medical Systems sign co-development agreement

    Horizon Discovery Group plc announces it has entered into a co-development and commercialisation agreement with Ventana Medical Systems, Inc., a member of the Roche Group.  The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as I ... more

  • Companies

    Horizon Discovery Ltd.

    We are a fully integrated life science company that provides enabling products, services and research programs to clients engaged at every stage of the healthcare continuum from sequence to treatment. Horizon was founded by Dr Chris Torrance and Professor Alberto Bardelli in 2007 when they ... more